The post-surgical use of antiviral treatments, including Tyzeka or telbivudine, 3TC or lamivudine, and Baraclude or entecavir, seems to cut the recurrence risk of hepatocellular carcinoma linked to hepatitis B, according to a study presented at the American Association for the Study of Liver Diseases' annual meeting and published online in the Journal of the American Medical Association. Just 20.5% of patients who received anti-HBV nucleoside analogs had cancer recurrence, compared with 43.6% of patients who didn't receive the drugs.